

Appl. No. 10/701,498
Amendment dated: June 17, 2005
Reply to OA of: December 17, 2004

Amendments to the Specification:

On page 12, please add the following subheading before the first full paragraph and replace the six paragraphs thereafter with the following amended paragraphs.

Brief Description of the Drawings

The invention will now be illustrated further by the following non-limiting Examples and by reference to the Figures, in which:

Figure 1 shows the HIV antigen concentration in human CD4 cells infected with HIV and treated with 4-butyl-4-hydroxy-2 (p-hydroxyphenyl) -1-phenyl-3, 5-pyrazolidinedione (4OH-OPB) or phenbutazone (PB) at various concentrations;

Figure 2 shows the effect of 4-butyl-4-hydroxy-2 (p-hydroxyphenyl) -1-phenyl-3, 5-pyrazolidinedione (4OH-OPB) when used in combination with AZT;

Figure 3 shows the effect of 4-butyl-4-hydroxy-2 (p-hydroxyphenyl) -1-phenyl-3, 5-pyrazolidinedione (4OH-OPB) when used in combination with indinavir; [[and;]]

Figure 4 shows the effect of 4-butyl-4-hydroxy-2 (p-hydroxyphenyl) -1-phenyl-3, 5-pyrazolidinedione (4OH-OPB) when used in combination with nevirapine; and

Figure 5 shows a 4OH-OPB acting together with 2',3'-dideoxyinosine (DDI);

A similar effect to those shown in figures 2-4 is seen when OPB is used in combination with 2',3'-dideoxyinosine (dal).